Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets
The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
Psammaplin A (11c) is a marine metabolite previously reported to be a potent inhibitor of two classes of epigenetic enzymes: histone deacetylases and DNA methyltransferases. The design and synthesis of a focused library based on the psammaplin A core has been carried out to probe the molecular features of this molecule responsible for its activity. By direct in vitro assay of the free thiol generated upon reduction of the dimeric psammaplin scaffold, we have unambiguously demonstrated that 11c functions as a natural prodrug, with the reduced form being highly potent against HDAC1 in vitro (IC(50) 0.9 nM). Furthermore, we have shown it to have high isoform selectivity, being 360-fold selective for HDAC1 over HDAC6 and more than 1000-fold less potent against HDAC7 and HDAC8. SAR around our focused library revealed a number of features, most notably the oxime functionality to be important to this selectivity. Many of the compounds show significant cytotoxicity in A549, MCF7, and W138 cells, with the SAR of cytotoxicity correlating to HDAC inhibition. Furthermore, compound treatment causes upregulation of histone acetylation but little effect on tubulin acetylation. Finally, we have found no evidence for 11c functioning as a DNMT inhibitor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, romidepsin and psammaplin A (Figure 15A) contain disulfide bridges that are reduced in the intracellular environment to generate free thiols that are capable of Zn2+-chelation (Figure 15B) [84, 85].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [84]
Citations
Cites
GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation
Hess, B., Kutzner, C., van der Spoel, D., & Lindahl, E. (2008) · Journal of Chemical Theory and Computation · doi:10.1021/ct700301q · Cited by 15,908
Spectrometric Identification of Organic Compounds
Silverstein, R. M., & Bassler, G. C. (1962) · Journal of Chemical Education · doi:10.1021/ed039p546 · Cited by 14,272
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling
Arnold, K., Bordoli, L., Kopp, J., & Schwede, T. (2006) · Bioinformatics · doi:10.1093/bioinformatics/bti770 · Cited by 6,988
Automatic atom type and bond type perception in molecular mechanical calculations
Wang, J., Wang, W., Kollman, P. A., & Case, D. A. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2005.12.005 · Cited by 5,477
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA
Ooi, S. K. T., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., Tempst, P., Lin, S.-P., Allis, C. D., et al. (2007) · Nature · doi:10.1038/nature05987 · Cited by 1,567
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Dnmt3L and the Establishment of Maternal Genomic Imprints
Bourc'his, D., Xu, G.-L., Lin, C.-S., Bollman, B., & Bestor, T. H. (2001) · Science · doi:10.1126/science.1065848 · Cited by 1,439
Research works printed but not linked: 4
- Fang M. Z., 2003, Cancer Res., 63, 7563
- Kim D., 1999, Anticancer Res., 19, 4085
- Furumai R., 2002, Cancer Res., 62, 4916
- Zhu Y., 2009, Mol. Med. Rep., 2, 743
Cited by
DNA methylation inhibitors in cancer: Recent and future approaches
Gros, C., Fahy, J., Halby, L., Dufau, I., Erdmann, A., Gregoire, J.-M., Ausseil, F., Vispé, S., & Arimondo, P. B. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.025 · Cited by 245
“Nevertheless, no DNA demethylation has been highlighted in HCT116 cells [195], and, in a recent study, psammaplin A exhibited no activity on DNMT1 at 30 and 120 mM [196], in agreement with the study of Lera et al.”
ResultTrials with ‘epigenetic’ drugs: An update
Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237
“…tumor cell growth in a A549 lung xenograft mouse model, DNMT inhibi- tion was not followed by DNA demethylation and re- expression of tumor suppressor genes, suggesting that an in- tracellular target different from DNMT1 is responsible for the cytotoxic effect of the molecule (Baud et al., 2012).”
BackgroundDiscovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries
Wang, X., Huang, B., Liu, X., & Zhan, P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.004 · Cited by 190
Recent progress in DNA methyltransferase inhibitors as anticancer agents
Zhang, Z., Wang, G., Li, Y., Lei, D., Xiang, J., Ouyang, L., Wang, Y., & Yang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072651 · Cited by 162
“, 2011), and it was further confirmed that histone deacetylases are the main target of Psammaplin and not DNMT (Baud et al., 2012).”
BackgroundFahy, J., Jeltsch, A., & Arimondo, P. B. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.729579 · Cited by 115
“Most recently, it was further confirmed that histone deacetylases are the main target of psammaplin and not DNMT [75].”
BackgroundAsgatay, S., Champion, C., Marloie, G., Drujon, T., Sénamaud‐Beaufort, C., Ceccaldi, A., Erdmann, A., Rajavelu, A., Schambel, P., Jeltsch, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401419p · Cited by 120
Weston, C. E., Krämer, A., Colin, F., Yıldız, Ö., Baud, M. G. J., Meyer‐Almes, F., & Fuchter, M. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00148 · Cited by 93
Self-citationMultitarget Drugs: an Epigenetic Epiphany
Ganesan, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201500394 · Cited by 93
Halsall, J. A., & Turner, B. M. (2016) · BioEssays · doi:10.1002/bies.201600070 · Cited by 83
Omari, N. E., Bakrim, S., Bakha, M., Lorenzo, J. M., Ребезов, М. Б., Shariati, M. A., Aboulaghras, S., Balahbib, A., Khayrullin, M., & Bouyahya, A. (2021) · Nutrients · doi:10.3390/nu13113714 · Cited by 89
Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Kim, E., Bisson, W. H., Löhr, C. V., Williams, D. E., Ho, E., Dashwood, R. H., & Rajendran, P. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150825125857 · Cited by 88
Wen, T., Song, L., & Hua, S. (2021) · Cancer Medicine · doi:10.1002/cam4.3660 · Cited by 80
Recent Advances in Small Peptides of Marine Origin in Cancer Therapy
Zhang, Q., Liu, Z.-D., Wang, Z., Wang, T., Wang, N., Wang, N., Zhang, B., & Yu-fen, Z. (2021) · Marine Drugs · doi:10.3390/md19020115 · Cited by 76
“Inducing S or S-G2/M phase cell cycle arrest; Inhibting HDAC P388; HCT-116; A549 (40 nM) [58,59]”
BackgroundNatural Products Impacting DNA Methyltransferases and Histone Deacetylases
Akoné, S. H., Ntie‐Kang, F., Stuhldreier, F., Ewonkem, M. B., Noah, A. M., Mouelle, S. E. M., & Müller, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00992 · Cited by 72
“Indeed, the reduced form of psammaplin A highly selectively inhibited HDAC1 with an IC50 value of 45 nM (Baud et al., 2012).”
BackgroundAnticancer Natural Compounds as Epigenetic Modulators of Gene Expression
Ratovitski, E. A. (2017) · Current Genomics · doi:10.2174/1389202917666160803165229 · Cited by 70
“Molecular mechanisms controlling cell cycle arrest, apoptosis, autophagy and necroptosis are closely related, so targeting these pathways simultaneously may help to induce the cell death of cancer cells and overcome the resistance of tumor cells to anticancer drugs [344-550].”
BackgroundFlorean, C., Schnekenburger, M., Lee, J., Kim, K. R., Mazumder, A., Song, S., Kim, J.-M., Grandjenette, C., Kim, J.-G., Yoon, A.-Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8210 · Cited by 61
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators
Zhan, P., Itoh, Y., Suzuki, T., & Liu, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00229 · Cited by 60
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
Frühauf, A., & Meyer‐Almes, F. (2021) · Molecules · doi:10.3390/molecules26175151 · Cited by 62
Self-citationIndole-Derived Psammaplin A Analogues as Epigenetic Modulators with Multiple Inhibitory Activities
Pereira, R., Benedetti, R., Pérez-Rodríguez, S., Nebbioso, A., García‐Rodríguez, J., Carafa, V., Stuhldreier, M. C., Conte, M., Rodríguez‐Barrios, F., Stunnenberg, H. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300618u · Cited by 62
Perspectives on natural product epigenetic modulators in chemical biology and medicine
Cherblanc, F., Davidson, R. W. M., Fruscia, P. D., Srimongkolpithak, N., & Fuchter, M. J. (2013) · Natural Product Reports · doi:10.1039/c3np20097c · Cited by 67
Self-citationNatural compounds in epigenetics: A current view
Miceli, M., Bontempo, P., Nebbioso, A., & Altucci, L. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.08.005 · Cited by 48
“5) derived from the actinomycete Streptomyces hygroscopicus, is a potent panHDACi (class I, II, IV).”
BackgroundInfluentialFrom natural products to HDAC inhibitors: An overview of drug discovery and design strategy
Qiu, X., Zhu, L., Wang, H., Tan, Y. L., Yang, Z., Yang, L., & Wan, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116510 · Cited by 52
Current Limitations And Future Opportunities For Epigenetic Therapies
Cherblanc, F., Chapman‐Rothe, N., Brown, R., & Fuchter, M. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.7 · Cited by 47
Self-citationIdentification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
Richard, K., Williams, D. E., de Silva, E. D., Brockman, M. A., Brumme, Z. L., Andersen, R. J., & Tietjen, I. (2018) · Viruses · doi:10.3390/v10070348 · Cited by 43
“However, while this screen instead identified only compounds of the HDACi and PKC activation classes, the results described here should not preclude future screening of natural product-derived compound libraries for additional LRAs which may act by novel mechanisms of action.”
BackgroundResultInfluentialSegretti, M. C. F., Vallerini, G. P., Brochier, C., Langley, B. C., Wang, L., Hancock, W. W., & Kozikowski, A. P. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00303 · Cited by 42
Pirola, L., Ciesielski, O., & Balcerczyk, A. (2018) · Cancers · doi:10.3390/cancers10080268 · Cited by 43
“In vitro studies have shown that PsA exerts strong cytotoxic effects in the human tumor cell lines A549, MCF7, and W138 and reduces tumor cell growth in a A549 lung xenograft mouse model [114].”
BackgroundCamptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors
Cincinelli, R., Musso, L., Artali, R., Guglielmi, M. B., Bianchino, E., Cardile, F., Colelli, F., Pisano, C., & Dallavalle, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.021 · Cited by 41
DNA Methyltransferase Inhibitors: Development and Applications
Lopez, M., Halby, L., & Arimondo, P. B. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43624-1_16 · Cited by 43
Jing, Q., Hu, X., Ma, Y.-Z., Mu, J., Liu, W., Xu, F., Li, Z., Bai, J., Hua, H., & Li, D. (2019) · Marine Drugs · doi:10.3390/md17070384 · Cited by 40
“Subsequently, this group synthesized a library of psammaplin A derivatives (Figure 7) by modifying the disulfide bond, the aromatic group substituents, and the oxime functionality, aiming to study the enzymatic selectivity and mechanism of action against DNA methyltransferases and histone deacetylases [92].”
BackgroundEpigenetic modulators from “The Big Blue”: A treasure to fight against cancer
Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.005 · Cited by 42
Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates
Bouyahya, A., Hachlafi, N. E., Aanniz, T., Bourais, I., Mechchate, H., Benali, T., Shariati, M. A., Burkov, P., Lorenzo, J. M., Wilairatana, P., et al. (2022) · Molecules · doi:10.3390/molecules27082568 · Cited by 42
Rabal, O., José‐Eneriz, E. S., Agirre, X., Sánchez-Arias, J. A., de Miguel, I., Ordóñez, R., Gárate, L., Miranda, E., Sáez, E., Vilas‐Zornoza, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02255 · Cited by 38
Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents
Hong, S., Shin, Y., Jung, M., Ha, M. W., Park, Y., Lee, Y., Shin, J., Oh, K. B., Lee, S. K., & Park, H. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.001 · Cited by 36
Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?
Moreira‐Silva, F., Camilo, V., Gaspar, V. M., Mano, J. F., Henrique, R., & Jerónimo, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050410 · Cited by 40
“Psammaplin A inhibits HDAC1 and HDAC6 activity, being more potent against HDAC1, reducing HDAC1 protein levels [61].”
BackgroundHan, L., Wang, T., Wu, J., Yin, X., Fang, H., & Zhang, N. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s118727 · Cited by 34
“The reduced products were prepared by in situ reduction of the respective disulfides using TCEP and used immediately (using the same agent and a similar method to that reported by Baud et al 35 ).”
Mohanty, I., Tapadar, S., Moore, S. G., Biggs, J. S., Freeman, C. J., Gaul, D. A., Garg, N., & Agarwal, V. (2021) · mSystems · doi:10.1128/msystems.01387-20 · Cited by 32
Natural Products as Zinc‐Dependent Histone Deacetylase Inhibitors
Tan, S., & Liu, Z. (2015) · ChemMedChem · doi:10.1002/cmdc.201402460 · Cited by 35
Molecular Targets of Active Anticancer Compounds Derived from Marine Sources
Song, X., Xiong, Y., Qi, X., Tang, W., Dai, J., Gu, Q., & Li, J. (2018) · Marine Drugs · doi:10.3390/md16050175 · Cited by 33
“fr m several marine sponges i cluding Pseudoce atina purpurea, was reported to be a potent inhibitor of HDAC [50,51].”
BackgroundLopez, M., Gilbert, J., Contreras, J., Halby, L., & Arimondo, P. B. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11454-0_17 · Cited by 36
Sponge Derived Bromotyrosines: Structural Diversity through Natural Combinatorial Chemistry
Niemann, H., Marmann, A., Lin, W., & Proksch, P. (2015) · Natural Product Communications · doi:10.1177/1934578x1501000143 · Cited by 31
Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
Baud, M. G. J., Leiser, T., Petrucci, V., Gunaratnam, M., Neidle, S., Meyer‐Almes, F., & Fuchter, M. J. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.11 · Cited by 34
Self-citationAanniz, T., Bouyahya, A., Balahbib, A., Kadri, K. E., Khalid, A., Makeen, H. A., Alhazmi, H. A., Omari, N. E., Zaid, Y., Wong, R. S.-Y., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.110907 · Cited by 30
Traore, M. D. M., Zwick, V., Simões‐Pires, C. A., Nurisso, A., Issa, M. E., Cuendet, M., Maynadier, M., Wein, S., Vial, H. J., Jamet, H., et al. (2017) · ACS Omega · doi:10.1021/acsomega.6b00481 · Cited by 31
Krishna, S., Shukla, S., Lakra, A. D., Meeran, S. M., & Siddiqi, M. I. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.05.014 · Cited by 28
Hashemi, P., & Sadowski, I. (2019) · Medicinal Research Reviews · doi:10.1002/med.21638 · Cited by 32
Divsalar, D. N., Simoben, C. V., Schonhofer, C., Richard, K., Sippl, W., Ntie‐Kang, F., & Tietjen, I. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00905 · Cited by 29
Oluwabusola, E. T., Katermeran, N. P., Poh, W. H., Goh, T. M. B., Tan, L. T., Diyaolu, O. A., Tabudravu, J. N., Ebel, R., Rice, S. A., & Jaspars, M. (2022) · Molecules · doi:10.3390/molecules27051721 · Cited by 28
“It has been reported that e pre nce of the oxime functionality is important for the isoform selectivity of ps mmaplin A on histone deac tylases [67].”
BackgroundNatural Products and Chemical Biology Tools: Alternatives to Target Epigenetic Mechanisms in Cancers
Lascano, S., Lopez, M., & Arimondo, P. B. (2018) · The Chemical Record · doi:10.1002/tcr.201800133 · Cited by 27
Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
Maietta, I., Martínez-Pérez, A., Álvarez, R., de Lera, Á. R., González‐Fernández, Á., & Simón‐Vázquez, R. (2022) · Pharmaceuticals · doi:10.3390/ph15070824 · Cited by 25
“Psammaplin A is a dimeric natural product that was originally isolated from an unidentified sponge, which displays antibacterial and antitumor activities by inhibition of both HDAC1 and DNMT1 [21,22].”
BackgroundHistone Deacetylase Inhibitors from Marine Invertebrates
Luparello, C., Mauro, M., Arizza, V., & Vazzana, M. (2020) · Biology · doi:10.3390/biology9120429 · Cited by 24
“Poecillastra wondoensis psammaplin A (e,z)-psammaplin A (e,e)-psammaplin A psammaplin E psammaplin K Activation of peroxisome proliferator-activated receptor γ (PPARγ) in MCF-7 cells and promotion of apoptotic death HDAC isoform selectivity Powerful inhibition of the proliferation and three-dimensional invasive growth…”
BackgroundInfluentialTriggering of Suicidal Erythrocyte Death by Psammaplin A
Bhuyan, A. A. M., Signoretto, E., & Lang, F. J. W. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447800 · Cited by 23
Lee, J., Orlikova, B., & Diederich, M. F. (2015) · Marine Drugs · doi:10.3390/md13084967 · Cited by 23
“Considering the important number of epigenetically active molecules also from marine origins, we speculate here in regards to marine compounds that would confer epigenetic regulation whether at the level of DNA methylation, histone modifications or small regulatory RNA expression, and hypothesize that marine natural c…”
BackgroundFluorescent analogs of the marine natural product psammaplin A: synthesis and biological activity
Hentschel, F., Sasse, F., & Lindel, T. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob25909e · Cited by 21
Biological and Biochemical Modulation of DNA Methylation
Lo, R., & Weksberg, R. (2014) · Epigenomics · doi:10.2217/epi.14.49 · Cited by 23
Aguiar, A. C. C., Parisi, J. R., Granito, R. N., de Sousa, L. R. F., Rennó, A. C. M., & Gazarini, M. L. (2021) · Marine Drugs · doi:10.3390/md19030134 · Cited by 23
“This effect can be also observed with a marine metabolite (Psammaplin A) and analogues, resulting in disruption of the epigenetic cell control and compromising the gene expression and cell survival [73,78].”
BackgroundWahi, A., Jain, P., Sinhari, A., & Jadhav, H. R. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02674-4 · Cited by 25
Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins
Zhou, Y., Li, J., Du, L., Mahdi, F., Le, T., Chen, W., Swanson, S. M., Watabe, K., & Nagle, D. G. (2018) · Marine Drugs · doi:10.3390/md16110442 · Cited by 25
“Previous studies reported that psammaplins inhibit histone deacetylase (HDAC) enzymes [17,18].”
BackgroundBao, Y. J., Xu, Q., Wang, L., Wei, Y., Hu, B., Wang, J., Liu, D., Zhao, L., & Jing, Y. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00369 · Cited by 20
Tareq, A. Z., Hyder, M. J., Hermida‐Merino, D., Mary, C. A., Kaur, A., Cooper, J. A., & Hayes, W. (2024) · Polymer · doi:10.1016/j.polymer.2024.127052 · Cited by 22
Baud, M. G. J., Haus, P., Leiser, T., Meyer‐Almes, F., & Fuchter, M. J. (2012) · ChemMedChem · doi:10.1002/cmdc.201200450 · Cited by 20
Self-citationGong, P., Li, K., Li, Y., Liu, D., Zhao, L., & Jing, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0602-1 · Cited by 19
Fotie, J., Matherne, C. M., Mather, J. B., Wroblewski, J. E., Johnson, K., Boudreaux, L. G., & Perez, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316854 · Cited by 17
Stopper, D., Biermann, L., Watson, P. R., Li, J., König, B., Gaynes, M. N., de Carvalho, L. P., Klose, J., Hanl, M., Hamacher, A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02373 · Cited by 20
Synthesis and Cytotoxicity of a Diazirine‐Based Photopsammaplin
Hentschel, F., Raimer, B., Kelter, G., Fiebig, H., Sasse, F., & Lindel, T. (2014) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201301717 · Cited by 16
Wen, J., Bao, Y. J., Niu, Q., Liu, J., Yang, J., Wang, W., Jiang, T., Fan, Y., Li, K., Wang, J., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.094 · Cited by 16
Medicinal chemistry advances in targeting class I histone deacetylases
Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00166 · Cited by 17
“Whereas in vitro experiments that lack reductants or hydrolases show increased IC50 values of such inhibitors [85, 86].”
BackgroundZhang, B., Liu, J., Gao, D., Yu, X., Wang, J., & Lei, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111672 · Cited by 14
Psammaplin A Improves Development and Quality of Somatic Cell Nuclear Transfer Mouse Embryos
Mallol, A., Santaló, J., & Ibáñez, E. (2014) · Cellular Reprogramming · doi:10.1089/cell.2014.0012 · Cited by 14
Yang, Y., Ang, W., Long, H., Chang, Y., Li, Z., Zhou, L., Yang, T., Deng, Y., & Luo, Y. (2016) · Scientific Reports · doi:10.1038/srep34711 · Cited by 15
Bagnall, N. H., Hines, B. M., Lucke, A. J., Gupta, P. K., Reid, R. C., Fairlie, D. P., & Kotze, A. C. (2017) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2017.01.001 · Cited by 14
“…ApexBio Mocetinostat Class I Fournel et al., 2008 ApexBio Thioester KD5170 Class I and II Hassig et al., 2008 ApexBio Disulfide Psammaplin A Class I Baud et al., 2012; Kim et al., 2007 Santa Cruz Biotech Thiolate TCS HDAC620b HDAC6 Suzuki et al., 2006 ApexBio Cyclic tetrapeptide Apicidin HDAC1;…”
BackgroundZhang, B., Shan, G., Zheng, Y., Yu, X., Ruan, Z., Li, Y., & Lei, X. (2019) · Marine Drugs · doi:10.3390/md17060333 · Cited by 12
“Psammaplin A, a member of a family of natural products isolated from some marine sponges, contains a similar side chain but with an amide bond instead of an olefin moiety (Figure 1) [19].”
Structure–Activity Relationship of Cytotoxic Natural Products from Indonesian Marine Sponges
Panggabean, J. A., Adiguna, S. P., Murniasih, T., Rahmawati, S. I., Bayu, A., & Putra, M. Y. (2022) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-021-00195-w · Cited by 11
Epigenetic mechanisms in cancer: push and pull between kneaded erasers and fate writers
Chang, H., Farooqı, A. A., Tang, J., Li, R., Ismail, M., Chang, Y., Shu, C., Yuan, S. F., Liu, J., Mansoor, Q., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s82527 · Cited by 13
“Psammaplin A (11c), a marine metabolite, was noted to be highly effective against HDAC1.(77)”
Synthesis of the molecular hybrid inspired by Largazole and Psammaplin A
Yu, X., Zhang, B., Shan, G., Wu, Y., Yang, F., & Lei, X. (2017) · Tetrahedron · doi:10.1016/j.tet.2017.12.025 · Cited by 11
Pharmacological Activities of Extracts and Compounds Isolated from Mediterranean Sponge Sources
Mannelli, L. D. C., Esposito, F. P., Sangiovanni, E., Pagano, E., Mannucci, C., Polini, B., Ghelardini, C., Dell’Agli, M., Izzo, A. A., Calapai, G., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14121329 · Cited by 12
Epigenetics: New Possibilities for Drug Discovery
Lundstrom, K. H. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0015 · Cited by 11
Meyners, C., Baud, M. G. J., Fuchter, M. J., & Meyer‐Almes, F. (2014) · Journal of Molecular Recognition · doi:10.1002/jmr.2345 · Cited by 11
“We previously reported the synthesis and HDAC inhibiting features of MB275, which is a hybrid compound of the natural product HDAC inhibitor psammaplin A (Baud et al., 2012).”
BackgroundSelf-citationSaima, S., Soni, I., Lavekar, A. G., Shukla, M., Equbal, D., Sinha, A. K., & Chopra, S. (2018) · Drug Development Research · doi:10.1002/ddr.21507 · Cited by 7
“According to CDC, S. aureus accounts for 80,461 infections and 11,285 deaths per year in the United States alone, which is more than HIV and TB combined, thus necessitating a dedicated drug discovery effort (Baud et al., 2012).”
BackgroundModular Oxime Formation by a trans‐AT Polyketide Synthase
Minas, H. A., François, R., Hemmerling, F., Fraley, A. E., Dieterich, C. L., Rüdisser, S., Meoded, R. A., Collin, S., Weissman, K. J., Gruez, A., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202304481 · Cited by 7
Identification of Pharmacological Targets Combining Docking and Molecular Dynamics Simulations
Ilizaliturri‐Flores, I., Luis, R. T. J., Vazquez, J. C., Vique‐Sánchez, J. L., Carrillo-Ibarra, N., Zamora-López, B., Reyes-López, C. A. S., Benítez‐Cardoza, C. G., Correa‐Basurto, J., & Zamorano‐Carrillo, A. (2013) · American Journal of Agricultural and Biological Sciences · doi:10.3844/ajabssp.2013.89.106 · Cited by 6
Properties and biotechnological applications of microbial deacetylase
Zou, S., Li, X., Huang, Y., Zhang, B., Tang, H. L., Xue, Y., & Zheng, Y. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12613-1 · Cited by 5
Manda, S. L. K., Ali, K., Chaturvedi, P., Meena, S., Datta, D. B., & Panda, G. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129173 · Cited by 5
Superacid and thiol-ene reactions for access to psammaplin analogues with HDAC inhibition activities
Bahhaj, F. E., Désiré, J., Blanquart, C., Martinet, N., Zwick, V., Simões‐Pires, C. A., Cuendet, M., Grégoire, M., & Bertrand, P. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.10.053 · Cited by 6
What is the Potential of Epigenetics in Drug Development?
Lundstrom, K. H. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.2 · Cited by 4
Avendaño, C., & Menéndez, J. C. (2023) · Medicinal Chemistry of Anticancer Drugs · doi:10.1016/b978-0-12-818549-0.00019-4 · Cited by 4
DNA Methylation: Biological Implications and Modulation of Its Aberrant Dysregulation
Lucidi, A., Tomaselli, D., Rotili, D., & Mai, A. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_12 · Cited by 3
Alvariño, R., Alfonso, A., Tabudravu, J. N., González-Jartín, J. M., Maqbali, K. S. A., Elhariry, M., Vieytes, M. R., & Botana, L. M. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00153 · Cited by 5
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00008-9 · Cited by 4
Jiang, Y., Tang, Y., Li, Y., Liu, L., Yue, K., Li, X., Qiu, P., Yin, R., & Jiang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116541 · Cited by 1
Vaske, Y. S. M., & Crews, P. (2013) · Wiley eBooks · doi:10.1002/9781118412893.ch1 · Cited by 1
“The spongederived probes jasplakinolide and psammaplin A are both important MDSM chemical probes and the reader is directed to recent literature surrounding their biological function (Boulant et al. 2011; Baud et al. 2012).”
BackgroundSmall molecules effective for disruption of HIV-1 latency
Hashemi, S. P. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0383231 · Cited by 1
Viviano, M. (2013) · Università degli Studi di Salerno · doi:10.14273/unisa-44
Surface Characterization and Reactivity of Methylammionium Lead Iodide
Zielinski, K. (2018) · Digital WPI
Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells
Wee, C. W., Kim, J. H., Kim, H. J., Kang, H., Suh, S. Y., Shin, B. S., Ma, E., & Kim, I. H. (2019) · Journal of Radiation Protection and Research · doi:10.14407/jrpr.2019.44.1.15
“More to the point, PsA showed an inhibitory activity against both DNMT and histone deacetylase [18-20].”
BackgroundModular Oxime Formation by a trans‐AT Polyketide Synthase
Minas, H. A., François, R. M. M., Hemmerling, F., Fraley, A. E., Dieterich, C. L., Rüdisser, S., Meoded, R. A., Collin, S., Weissman, K. J., Gruez, A., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202304481
Bulygin, A. A., Davletgildeeva, A. T., & Kuznetsov, N. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104560 · Cited by 1
“It was also shown to inhibit the histone deacetylase HDAC1 with IC50 = 1 nM, and later studies established that HDAC1 is the only target of psammaplin A [169].”
Huang, J., Liu, J., Chong, C., Guo, Y., & Jin, X. (2026) · Chemistry · doi:10.3390/chemistry8100145
BindingDB (2016) · UC San Diego · doi:10.7270/q2qz2csd
Metadata
- Authors
- Baud, M. G. J., Leiser, T., Haus, P., Samlal, S., Wong, A. C., Wood, R. J., Petrucci, V., Gunaratnam, M., Hughes, S. M., Buluwela, L., Turlais, F., Neidle, S., Meyer-Almes, F.-J., White, A. J. P., & Fuchter, M. J.
- Affiliations
- Imperial College London (GB)
- Darmstadt University of Applied Sciences (DE)
- Cancer Research Technology Discovery Laboratories, Wolfson Institute for Biomedical Research, The Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom
- Cancer Research UK (GB)
- Department of Surgery and Cancer, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom
- Department of Chemical Engineering and Biotechnology, University of Applied Sciences, Schnittspahnstrasse 12, 64287 Darmstadt, Germany
- Corresponding author
- Fuchter, Matthew J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-02-09
- Volume
- 55
- Issue
- 4
- Pages
- 1731-1750
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2064944074
- Cited by
- 100
- References
- 81
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 7 · 2022: 6 · 2021: 10 · 2020: 5 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 12 · 2014: 7 · 2013: 6 · 2012: 7
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
- Keywords
- psammaplin A, histone deacetylase inhibitors, HDAC1, HDAC isoform selectivity, structure-activity relationship, marine natural products, cytotoxicity, histone acetylation, DNA methyltransferase inhibition, focused libraries
- MeSH terms
- Acetylation, Antineoplastic Agents, Disulfides, DNA (Cytosine-5-)-Methyltransferases, Drug Screening Assays, Antitumor, Histones, Humans, Isoenzymes, Models, Molecular, Prodrugs, Structure-Activity Relationship, Tubulin, Tyrosine, Crystallography, X-Ray, Dimerization, Epigenesis, Genetic, Cell Line, Tumor, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.